Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B

BACKGROUND Nucleoside/nucleotide analogs are currently the core drugs for antiviral treatment of chronic hepatitis B (CHB). Among them, entecavir (ETV) and tenofovir alafenamide fumarate (TAF) exhibit potent antiviral effects with low resistance rates and are recommended as first-line treatment regimens in domestic and international guidelines. AIM To evaluate bone and renal safety in patients with CHB receiving initial treatment with TAF or ETV. METHODS This study included 95 treatment-naive pa